CureVac
mRNA therapeutics pioneer acquired by BioNTech (Jan 2025) — CV8102 adjuvant and thermostable mRNA formulation technology for vaccines and oncology.
- Country
- Germany
- Revenue
- ~$50M
- Employees
- ~200 emp
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| mRNA platforms & LNP delivery | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.